The latest trend in metabolic health is undoubtedly centered around GLP-1 receptor agonists , and BrightMeds is spearheading this shift. These groundbreaking drugs, initially designed for treating type 2 diabetes, are now commonly prescribed – or considered – for their significant ability to prom